Interleukin-17 (IL-17) is a recently cloned cytokine that is exclusively pr
oduced by activated T cells, but its receptor has been found on several cel
ls and tissues, Like other proinflammatory cytokines produced by activated
T cells, IL-17 may affect osteoclastic resorption and thereby mediate bone
destruction accompanying some inflammatory diseases. In the present study,
we investigated whether osteogenic cells possess the receptor for IL-17 (IL
-17R) and whether IL-17 affects osteoclastic resorption, We found that IL-1
7R mRNA is expressed both in mouse MC3T3-E1 osteoblastic cells and fetal mo
use long bones, suggesting that osteogenic cells may be responsive to IL-17
, In fetal mouse long bones, IL-17 had no effect on basal and IL-1 beta-sti
mulated osteoclastic bone resorption, but when given together with tumor ne
crosis factor-alpha (TNF-alpha) it increased bone resorption dose dependent
ly in serum-free conditions. In addition, IL-17 increased TNF-alpha-induced
IL-1 alpha, IL-1 beta, and IL-6 mRNA expression in fetal mouse metatarsals
and IL-1 alpha and IL-6 mRNA expression in MC3T3-E1 cells. In conclusion,
IL-17R mRNA was expressed by mouse osteoblastic cells and fetal mouse long
bones, and IL-17 in combination with TNF-alpha, but not IL-1 beta, increase
d osteoclastic resorption in vitro. IL-17 may therefore affect bone metabol
ism in pathological conditions characterized by the presence of activated T
cells and TNF-alpha production such as rheumatoid arthritis and loosening
of bone implants.